Vasohibin (VASH) -1 and -2 are novel angiogenic regulators. The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC). A total of 209 patients with ESCC were investigated. Resected tumor specimens were immunostained using anti-CD34 antibody, anti-VASH1 antibody and anti-VASH2 antibody. The ratio of the microvessels density and the VASH1 density as the VASH1-positive ratio were defined and the patients were divided into two groups (a high VASH1 group and a low VASH1 group) according to the average value. The patients were also divided into two groups (a high VASH2 group and a low VASH2 group) according to VASH2 expression upon immunostaining. The clinical outcomes of these two groups were then evaluated. The high VASH1 group contained 106 patients (50.7%). The high VASH2 group contained 48 patients (23.0%). Long-term survival was significantly poorer in the high VASH1 group compared with that in the low VASH1 group. A slight correlation between VASH1 expression and VASH2 expression was observed. The low VASH1/low VASH2 group had a better prognosis than the other three groups with different combinations of VASH1 and VASH2 expression levels. The present study showed that high VASH1 expression and high VASH2 expression may be novel independent predictors of a poor prognosis in patients with ESCC and that a slight correlation between VASH1 and VASH2 expression existed. The present findings suggest that combined evaluation of VASH1 and VASH2 expression should provide an improved understanding of their clinicopathological features.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144939 | PMC |
| http://dx.doi.org/10.3892/ol.2018.9249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventive effects of vasohibin-2-targeting peptide vaccine for diabetic nephropathy.
Am J Physiol Renal Physiol
June 2024
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Diabetic nephropathy remains the leading cause of end-stage kidney disease in many countries, and additional therapeutic targets are needed to prevent its development and progression. Some angiogenic factors are involved in the pathogenesis of diabetic nephropathy. Vasohibin-2 (VASH2) is a novel proangiogenic factor, and our previous study showed that glomerular damage is inhibited in diabetic homozygous knockout mice.
View Article and Find Full Text PDFHigh Vasohibin-2 expression correlated with autophagy in proliferative diabetic retinopathy.
Exp Eye Res
March 2024
Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, 210009, China. Electronic address:
Article Synopsis
- The study investigates the role of Vasohibin-2 (VASH2) in angiogenesis, particularly in proliferative diabetic retinopathy (PDR), by analyzing vitreous levels in 120 eyes.
- Results show significantly higher levels of VASH2 in PDR patients compared to those with epiretinal membranes or macular holes, indicating its potential involvement in disease progression.
- Findings suggest that VASH2 enhances the migration of human retinal microvascular endothelial cells (HRMECs) and promotes autophagy, highlighting its potential as a novel target for anti-angiogenic therapies in PDR.
Vasohibin-2-Targeting Therapies for the Treatment of Pancreatic Ductal Adenocarcinoma.
Tohoku J Exp Med
March 2024
New Industry Creation Hatchery Center, Tohoku University.
As pancreatic ductal adenocarcinoma (PDAC) is extremely malignant and refractory, therapeutic options for this cancer are anticipated worldwide. We isolated vasohihibin-2 (VASH2) and observed its overexpression in various types of cancer. We then noticed that upregulated expression of VASH2 in patients with PDAC resulted in a conspicuous reduction in the postoperative survival period and further revealed that the abrogation of Vash2 expression in pancreatic cancer cells inhibited its growth and metastasis and augmented tumor infiltration of CD8 cells in the mouse model.
View Article and Find Full Text PDFA preliminary study on the mechanism of VASH2 in childhood medulloblastoma.
Sci Rep
October 2023
Department of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
To study the differences in VASH2 expression in pediatric medulloblastoma (MB) tumor tissues of different molecular subtypes, to analyze the correlation between VASH2 and the molecular subtypes of medulloblastoma, clinicopathological data, and prognosis, and to explore the specific mechanism of VASH2's role in SHH medulloblastoma cell lines DAOY. We analyzed 47 pediatric medulloblastoma cases admitted to the Department of Pediatric Neurosurgery of the First Affiliated Hospital of Xinjiang Medical University from January 2011 to December 2019, and the expression levels of YAP1 and GAB1 in these tumor tissues were detected by immunohistochemistry (IHC) and molecularly typed (WNT-type, SHH-type, and non-WNT/SHH-type). The correlation between VASH2 and molecular typing of medulloblastoma was analyzed.
View Article and Find Full Text PDFDevelopment of a Novel and Simple Anti-Metastatic Cancer Treatment Targeting Vasohibin-2.
Tohoku J Exp Med
November 2023
Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University.
Article Synopsis
- Researchers identified VASH2, a protein linked to tumor progression, as a target for cancer therapy and developed a vaccine aimed at it.
- They created two specific peptide sequences, MTG and RRR, and tested the MTG peptide, which prompted a stronger immune response against VASH2 compared to the RRR peptide.
- In mouse models, the MTG peptide vaccine significantly reduced cancer cell invasion and metastasis, suggesting it could be an effective treatment option for aggressive cancers, including pancreatic cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!